AR014768A1 - Medicamento para evitar o tratar los tumores especificos de los virus del papiloma humano que contiene por lo menos una proteina de fusion de por lomenos una proteina l1 de uno o mas virus del papiloma y de por lo menos una proteina e de uno o mas virus de papiloma, un procedimiento para su preparac - Google Patents
Medicamento para evitar o tratar los tumores especificos de los virus del papiloma humano que contiene por lo menos una proteina de fusion de por lomenos una proteina l1 de uno o mas virus del papiloma y de por lo menos una proteina e de uno o mas virus de papiloma, un procedimiento para su preparacInfo
- Publication number
- AR014768A1 AR014768A1 ARP990101310A ARP990101310A AR014768A1 AR 014768 A1 AR014768 A1 AR 014768A1 AR P990101310 A ARP990101310 A AR P990101310A AR P990101310 A ARP990101310 A AR P990101310A AR 014768 A1 AR014768 A1 AR 014768A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- papiloma
- viruses
- fusion
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Medicamento para evitar o para tratar el tumor específico del virus del papiloma humano, el HPV (Human Papillomavirus), que contiene por lo menos unaproteína obtenida por la fusion de por lo menos una proteína L1 de uno o más virus del papiloma y de por lo menos una proteína E de uno o más virus delpapiloma y eventualmente sustancias aditivas o auxiliares adecuadas, no conteniendo la proteína de fusion ningun epítope no específico delpapilomavirus, procedimiento para su preparacion y utilizacion de una proteína de fusion para la preparacion de un medicamento destinado por una parte parainhibir los tumores HPV-específicos y destinado por otra parte a la regresion de tumores HPV-específicos ya existentes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19812941A DE19812941A1 (de) | 1998-03-24 | 1998-03-24 | Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR014768A1 true AR014768A1 (es) | 2001-03-28 |
Family
ID=7862148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101310A AR014768A1 (es) | 1998-03-24 | 1999-03-24 | Medicamento para evitar o tratar los tumores especificos de los virus del papiloma humano que contiene por lo menos una proteina de fusion de por lomenos una proteina l1 de uno o mas virus del papiloma y de por lo menos una proteina e de uno o mas virus de papiloma, un procedimiento para su preparac |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1064014B1 (es) |
| JP (1) | JP2002509863A (es) |
| AR (1) | AR014768A1 (es) |
| AT (1) | ATE288279T1 (es) |
| AU (1) | AU755242B2 (es) |
| CA (1) | CA2323573A1 (es) |
| DE (2) | DE19812941A1 (es) |
| DK (1) | DK1064014T3 (es) |
| ES (1) | ES2237913T3 (es) |
| MX (1) | MXPA00009282A (es) |
| PT (1) | PT1064014E (es) |
| WO (1) | WO1999048518A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE514982C2 (sv) * | 1999-09-30 | 2001-05-28 | Active Biotech Ab | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning |
| DE10059630A1 (de) * | 2000-12-01 | 2002-06-06 | Medigene Ag | Arzneimittel zur Vermeidung oder Behandlung von durch humanen Papillomavirus-Typ 18-hervorgerufenem Tumor |
| ATE424409T1 (de) † | 2002-05-17 | 2009-03-15 | Univ Cape Town | Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel |
| JP5186678B2 (ja) * | 2005-10-13 | 2013-04-17 | 財団法人ヒューマンサイエンス振興財団 | 経皮抗原投与のための抗原キット |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4435907C2 (de) * | 1994-10-07 | 1997-07-24 | Lutz Prof Dr Gissmann | Papillomavirusähnliche Partikel und deren Anwendung |
-
1998
- 1998-03-24 DE DE19812941A patent/DE19812941A1/de not_active Ceased
-
1999
- 1999-03-24 AT AT99916884T patent/ATE288279T1/de not_active IP Right Cessation
- 1999-03-24 MX MXPA00009282A patent/MXPA00009282A/es active IP Right Grant
- 1999-03-24 EP EP99916884A patent/EP1064014B1/de not_active Expired - Lifetime
- 1999-03-24 JP JP2000537565A patent/JP2002509863A/ja active Pending
- 1999-03-24 DK DK99916884T patent/DK1064014T3/da active
- 1999-03-24 AR ARP990101310A patent/AR014768A1/es unknown
- 1999-03-24 DE DE59911556T patent/DE59911556D1/de not_active Expired - Fee Related
- 1999-03-24 AU AU35214/99A patent/AU755242B2/en not_active Ceased
- 1999-03-24 WO PCT/EP1999/001996 patent/WO1999048518A2/de active IP Right Grant
- 1999-03-24 CA CA002323573A patent/CA2323573A1/en not_active Abandoned
- 1999-03-24 PT PT99916884T patent/PT1064014E/pt unknown
- 1999-03-24 ES ES99916884T patent/ES2237913T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE19812941A1 (de) | 1999-10-07 |
| DK1064014T3 (da) | 2005-05-30 |
| WO1999048518A3 (de) | 1999-12-02 |
| CA2323573A1 (en) | 1999-09-30 |
| EP1064014B1 (de) | 2005-02-02 |
| ES2237913T3 (es) | 2005-08-01 |
| WO1999048518A2 (de) | 1999-09-30 |
| AU755242B2 (en) | 2002-12-05 |
| DE59911556D1 (de) | 2005-03-10 |
| MXPA00009282A (es) | 2002-12-13 |
| AU3521499A (en) | 1999-10-18 |
| JP2002509863A (ja) | 2002-04-02 |
| ATE288279T1 (de) | 2005-02-15 |
| PT1064014E (pt) | 2005-06-30 |
| EP1064014A2 (de) | 2001-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR199903053T2 (xx) | Benzimidazol t�revleri. | |
| PT1319007E (pt) | Compostos de succinimida heterociclicos fundidos e seus analogos enquanto moduladores da funcao dos receptores hormonais nucleares | |
| UY26724A1 (es) | Métodos y composiciones para tratar el virus de la hepatitis c | |
| ES2080307T3 (es) | Composiciones farmaceuticas. | |
| ECSP077349A (es) | Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias | |
| AR032912A1 (es) | Formulacion farmaceutica | |
| CY1111193T1 (el) | Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους | |
| ES2194308T3 (es) | Utilizacion de sustancias con una actividad de oxitocina en la preparacion de medicamentos para la curacion de heridas. | |
| AR035348A1 (es) | Indoles sustituidos, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la preparacion de medicamentos | |
| ES2062392T3 (es) | Medicamentos que comprenden salmeterol y fluticasona. | |
| HUP0103484A2 (hu) | Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára | |
| ATE556704T1 (de) | Pulverinhalator-formulierungen | |
| BR0115162A (pt) | Tratamentos antitumorais eficazes | |
| ATE360628T1 (de) | Sulfonamide und deren derivate als modulatoren der endothelin-aktivität | |
| ES2190205T3 (es) | Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda. | |
| ES2164914T3 (es) | Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar. | |
| AR032151A1 (es) | Uso de un farmaco anti-angiogenico en conjunto con un agente fotosensible para la preparacion de un medicamento para el tratamiento fotodinamico mejorado de la neovasculatura indeseada | |
| BR0112807A (pt) | Derivados de indol e sua aplicação como medicamento | |
| AR014768A1 (es) | Medicamento para evitar o tratar los tumores especificos de los virus del papiloma humano que contiene por lo menos una proteina de fusion de por lomenos una proteina l1 de uno o mas virus del papiloma y de por lo menos una proteina e de uno o mas virus de papiloma, un procedimiento para su preparac | |
| WO2015048503A3 (en) | N-arylmethyl sulfonamide negative modulators of nr2a | |
| TW200501935A (en) | Use of resveratrol for preparation of a medicament useful for the treatment of influenza virus infections | |
| EA199800526A1 (ru) | Производные бензимидазола и их применение для лечения вирусных инфекций | |
| BR112021024138A2 (pt) | Sistema para administração supervisionada eletronicamente de uma composição farmacêutica | |
| EA200101240A1 (ru) | Использование мелатонина в медицине | |
| ES2059130T3 (es) | Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |